A Phase 1 trial of the safety, tolerability, and biological effects of intravenous enadenotucirev (EnAd), a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)
ASTRO Poster Library, Sean O'Cathail,
390114